Andere talen IntelGenx Technologies Corp.

Aandelen

IGXT

US45822R1014

Vertraagde tijd OTC Markets Andere beurzen 18:28:08 06-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,175 ^USD	-2,23%		+9,38%	+26,72%

08/04	Intelgenx kondigt aan dat de eerste Parkinson-patiënten gedoseerd zijn met Montelukast Versafilm® in Fase 2 "Montpark? Klinische Studie	CI
05/04	IntelGenx vernieuwt status van Buprenorfine Buccale Film ANDA	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial	08/04
Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	08/04
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	08/04
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	05/04
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	05/04
IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA	05/04
IntelGenx Technologies Narrows Q4 Loss, Revenue Rises	21/03
IntelGenx Technologies Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results	21/03
IntelGenx Technologies : 25 10.42pm MOCK-UP with special characters / * $ % + ` ' ' `	15/03
IntelGenx Technologies : 26 10.45pm MOCK-UP with special characters / * $ % + ` ' ' `	15/03
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow	14/03
IntelGenx Subsidiary Signs Third Amended, Restated Loan Agreement With atai Life Sciences	11/03
IntelGenx Brief: Entering Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11/03
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11/03
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11/03
IntelGenx Technologies Corp. announced that it expects to receive $2 million in funding	08/03
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering	20/02
IntelGenx Brief: Launching Regulation A Offering of Up to 2 Million shares In Series A Convertible Cumulative Preferred Stock, Par Value $0.00001 Per Share, at an Offering Price of $10.00 Each, For a Max Offering amount of $20 Million	20/02
IntelGenx Technologies Corp. announced that it expects to receive $20 million in funding	14/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen IntelGenx Technologies Corp.

Aandelen

IGXT

US45822R1014

Andere talen

Filters